Abstract:Chimeric antigen receptors (CAR)-T cells are genetically engineered T-lymphocytes redirected with a predefined specificity to any target antigen, in a non-HLA restricted manner, therefore combining antibody-type specificity with effector T-cell function. This strategy was developed some thirty years ago, after extensive work established the key role of the immune system against cancer. The first-engineered T-cell with chimeric molecule was designed in 1993 by Israeli immunologist Zelig Eshhar. Since then, several modifications took place, including the addition of co-stimulatory domain, to further improve CAR-T cell anti-tumor potency. The first clinical application of CAR-T cell was done in Rotterdam in 2005 for metastatic renal cell carcinoma and simultaneously at the National Cancer Institute (NCI) for metastatic ovarian cancer. These pioneered studies failed to demonstrate a therapeutic benefit, but warning emerged concerning their safety of use. The real clinical success came with anti-CD19 CAR-T cells, used since 2009 by Steven Rosenberg at the NCI in a patient with refractory follicular lymphoma and in 2011 by Carl June and David Porter from the University of Pennsylvania in patients with chronic lymphocytic leukemia and B-cell acute lymphoblastic leukemia. From that time, large centers in North America have embarked in several early phase and pivotal trials that have demonstrated unprecedent response rate in heavily pretreated chemo refractory patient with B-cell malignancies. Theses clinical success have led to the approval of three anti-CD19 CAR-T cells products for the management of B-cell malignancies in the United States and in Europe as of December 2020.

CAR T-cell Therapy: A New Era in Cancer Immunotherapy

CAR‐T Therapy in Clinical Practice: Technical Advances and Current Challenges

CAR T-Cell-Based gene therapy for cancers: new perspectives, challenges, and clinical developments

CAR-T cell therapy: a game-changer in cancer treatment and beyond

CAR‐T cell therapy: A breakthrough in traditional cancer treatment strategies (Review)

Evolving CAR-T-Cell Therapy for Cancer Treatment: From Scientific Discovery to Cures

CAR T-Cell Therapy: The Next Frontier for Cancer Immunotherapy

CAR-cell therapy in the era of solid tumor treatment: current challenges and emerging therapeutic advances

From bench to bedside: the history and progress of CAR T cell therapy

Revolutionizing cancer treatment: an in-depth exploration of CAR-T cell therapies

CAR T cells: Building on the CD19 paradigm

CAR T-cell immunotherapy: The path from the by-road to the freeway?

Clinical practice: chimeric antigen receptor (CAR) T cells: a major breakthrough in the battle against cancer

Cutting-Edge CAR Engineering: Beyond T Cells

Investigating chimeric antigen receptor T cell therapy and the potential for cancer immunotherapy (Review)

Advanced Strategies of CAR-T Cell Therapy in Solid Tumors and Hematological Malignancies

Current progress in CAR-T cell therapy for tumor treatment

Harnessing the potential of CAR-T cell therapy: progress, challenges, and future directions in hematological and solid tumor treatments

Advances and Hurdles in CAR T Cell Immune Therapy for Solid Tumors

Therapeutic Potential of T Cell Chimeric Antigen Receptors (CARs) in Cancer Treatment: Counteracting Off-Tumor Toxicities for Safe CAR T Cell Therapy

CAR-T cells, from principle to clinical applications